Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + Iparomlimab + Tuvonralimab as neoadjuvant therapy for locally advanced cervical cancer (Phase II, single-arm)
ChiCTR2600116767Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan, iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathological complete response rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecaniparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600116767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116767.